Analyst Ratings January 26, 2026

BTIG Starts Coverage on Fannie Mae, Assigns Buy Rating and $20 Target

Analyst cites potential re-rating if Treasury’s Senior Preferred Stock is resolved and capital rules are eased

By Sofia Navarro FNMA
BTIG Starts Coverage on Fannie Mae, Assigns Buy Rating and $20 Target
FNMA

BTIG has initiated coverage of Fannie Mae (OTC: FNMA) with a Buy rating and set a $20.00 price target, identifying potential upside tied to the treatment of Treasury’s Senior Preferred Stock and possible regulatory capital relief. The firm highlighted that Treasury warrants representing 79.9% of common equity and any change to the Senior Preferred Stock could prompt an immediate valuation re-rating while reduced capital requirements could support longer-term gains. The stock currently trades at $8.87, with a market capitalization of $50.9 billion, and carries a 12-month price return of 54.53% since President Trump took office.

Key Points

  • BTIG initiates coverage with a Buy rating and $20.00 target for FNMA, citing capital-structure catalysts.
  • Treasury exercising warrants for 79.9% of common stock could be a key step toward exiting conservatorship and validating valuation.
  • Lower capital requirements could enable technology investment to speed underwriting and potentially spur housing activity.

BTIG opened coverage on Fannie Mae (OTC: FNMA) on Monday, assigning a Buy rating and a $20.00 price target. The research note emphasized potential upside tied to the company’s capital structure and regulatory framework.

At the time BTIG issued its view, Fannie Mae shares were quoted at $8.87, giving the mortgage finance company a market capitalization of $50.9 billion. The firm observed that the stock has risen substantially over the prior year - recording a 54.53% price return over the past 12 months since President Trump took office.

BTIG pointed to a specific capital event it believes could materially affect valuation: Treasury exercising warrants that would equate to ownership of 79.9% of FNMA’s common stock. The firm described that outcome as potentially "the most seamless and rational starting point towards an eventual exit from conservatorship" and said it could help establish a clearer fundamental valuation for the company.

In the near term, BTIG said resolving the Senior Preferred Stock held by the Treasury could alone support an immediate re-rating of the shares. The research note added that combining that step with lower capital requirements under the Enterprise Regulatory Capital Framework would create additional upside over both near and longer-term horizons.

BTIG also commented on how regulatory relief could affect operations. The firm suggested that reduced capital demands could free resources for technology investments that make loan underwriting faster and less costly - a change BTIG labeled as "the most sustainable way to help spur housing activity and create long-term value."

The report acknowledged existing headwinds for Fannie Mae, including a negative earnings-per-share figure of $0.34 and analysts' expectations that the company will not return to profitability this year. BTIG's analysis therefore frames potential gains as contingent on regulatory and capital-structure developments rather than on current profitability trends.

InvestingPro data included in the coverage note flagged that the stock's relative strength index (RSI) indicates it is in overbought territory, a technical observation BTIG noted alongside its fundamental case. For readers seeking expanded commentary, the note referenced InvestingPro as offering comprehensive analysis with additional ProTips and a detailed research report on Fannie Mae.


Summary

  • BTIG initiates coverage of Fannie Mae with a Buy rating and a $20.00 price target.
  • Fannie Mae shares trade at $8.87 with a market capitalization of $50.9 billion and a 12-month return of 54.53% since President Trump took office.
  • BTIG highlights potential valuation upside tied to Treasury actions on Senior Preferred Stock and to lower capital requirements under the Enterprise Regulatory Capital Framework.

Key points

  • Capital-structure resolution: Treasury exercising warrants for 79.9% of common stock could start a pathway out of conservatorship and help validate a more accurate fundamental valuation - impacting the mortgage finance sector and broader housing finance markets.
  • Regulatory relief matters: Addressing Senior Preferred Stock alone could prompt an immediate re-rating, while pairing that with reduced capital requirements could provide both near-term and sustained upside - relevant to banks, mortgage lenders, and housing market participants.
  • Operational investment: Lower capital requirements could allow Fannie Mae to invest more in technology to speed and reduce the cost of underwriting, a factor that could influence mortgage origination economics.

Risks and uncertainties

  • Regulatory uncertainty - The timing and outcome of any actions related to the Senior Preferred Stock and exercising of Treasury warrants are uncertain; changes (or lack thereof) would directly affect valuation and conservatorship status.
  • Profitability concerns - Fannie Mae reported a negative EPS of $0.34 and analysts do not expect the company to be profitable this year, which constrains upside absent capital-structure or regulatory change.
  • Technical overextension - InvestingPro data indicates the stock's RSI is in overbought territory, which may signal near-term price risk for equity investors.

Risks

  • Uncertain regulatory actions regarding the Senior Preferred Stock and Treasury warrants could delay or negate the anticipated re-rating.
  • Fannie Mae’s negative EPS of $0.34 and lack of expected profitability this year limit upside absent structural changes.
  • Technical indicators show the stock may be overbought, posing short-term price risk to investors.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026